Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Autosomal Dominant Polycystic Kidney Disease (ADPKD)

In brief

This is a Phase 1, First-in-Human study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of PYC-003 in healthy adult participants and adult participants with confirmed PKD1 mutation-associated Autosomal Dominant Polycystic Kidney Disease (ADPKD) There are 4 parts in this study, i.e. Part A, Part B, Part C and Part D.

Key facts

Study ID
NCT06714006
Run by
PYC Therapeutics
People needed
166
Starts
2025-04-07
Expected to finish
2028-11-01
Last updated by the study team
2026-07-27

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.